Suvorexant for the treatment of insomnia

References

• Herring WJ, Ma J, Snyder E, et al. EEG power spectral profile of the orexin receptor antagonist suvorexant (MK-4305) in patients with primary insomnia and in healthy subjects. Sleep 2012;35:A222-A22
   Google Scholar
• Herring WJ, Ma JS, Snyder E, et al. Power spectral profile of the orexin receptor antagonist suvorexant (MK-4305) in primary insomnia patients and healthy-subjects. Biol Psychiatry 2012;71:297S-8S
   Google Scholar
• Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia a randomized clinical trial of suvorexant. Neurology 2012;79:2265-74
   PubMed Web of Science ®Google Scholar
• Herring WJ, Snyder E, Paradis E, et al. Suvorexant, an orexin receptor antagonist, in preventing symptom return in patients with insomnia after 1 year of treatment: a randomised, double-blind, placebo-controlled study. J Sleep Res 2012;21:351-1
   Google Scholar
• Ivgy-May N, Leibensperger H, Froman S, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #2). J Sleep Res 2012;21:351-2
   Google Scholar
• Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013;36:259-67
   PubMed Web of Science ®Google Scholar
• Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:461-71
   PubMed Web of Science ®Google Scholar
• Farkas R. Suvorexant safety and efficacy. U.S. Food and Drug Administration. 2013. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM354215.pdf [Last accessed 10 September 2014]
   Google Scholar
• Suvorexant. Advisory Committee Briefing Document. 2013. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM352970.pdf [Last accessed 10 September 2014]
   Google Scholar
• DEA. Drug Enforcement Administration, U.S. Department of Justice. Schedules of controlled substances: placement of suvorexant into Schedule IV. Final rule. Fed Regist 2014;79:51243-7
   PubMedGoogle Scholar
• Coleman PJ, Schreier JD, Cox CD, et al. Discovery of (2r,5r)-5-{ (5-fluoropyridin-2-yl)oxy methyl}-2-methylpiperidin-1-yl 5 -methyl-2-(pyrimidin-2-yl)phenyl methanone (mk-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. Chem Med Chem 2012;7:415-24
   Google Scholar
• Winrow CJ, Gotter AL, Cox CD, et al. Pharmacological characterization of mk-6096-a dual orexin receptor antagonist for insomnia. Neuropharmacology 2012;62:978-87
   PubMed Web of Science ®Google Scholar
• Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13:150-5
   PubMed Web of Science ®Google Scholar
• Hoever P, de Haas S, Dorffner G, et al. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol (Oxf) 2012;26:1071-80
   PubMed Web of Science ®Google Scholar
• Hoever P, de Haas S, Winkler J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 2010;87:593-600
   PubMed Web of Science ®Google Scholar
• Hoever P, Dorffner G, Benes H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 2012;91:975-85
   PubMed Web of Science ®Google Scholar
• Hoever P, Hay J, Rad M, et al. Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects. J Clin Psychopharmacol 2013;33:363-70
   PubMed Web of Science ®Google Scholar
• Actelion/GlaxoSmithKline. Actelion and GSK discontinue clinical development of almorexant. 2011. Available from: www.actelion.com/en/investors/media-releases/index.page?newsId=1483135 [Last accessed 10 September 2014]
   Google Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and g protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85
   PubMed Web of Science ®Google Scholar
• de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322-7
   PubMed Web of Science ®Google Scholar
• Gotter AL, Webber AL, Coleman PJ, et al. International union of basic and clinical pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacol Rev 2012;64:389-420
   PubMed Web of Science ®Google Scholar
• Coleman PJ, Cox CD, Roecker AJ. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia. Curr Top Med Chem 2011;11:696-725
   PubMedGoogle Scholar
• Coleman PJ, Schreier JD, Roecker AJ, et al. Discovery of 3,9-diazabicyclo 4.2.1 nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat. Bioorg Med Chem Lett 2010;20:4201-5
   PubMedGoogle Scholar
• Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist (7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl 5-met hyl-2-(2h-1,2,3-triazol-2-yl)phenyl methanone (mk-4305) for the treatment of insomnia. J Med Chem 2010;53:5320-32
   PubMed Web of Science ®Google Scholar
• Winrow CJ, Gotter AL, Cox CD, et al. Promotion of sleep by suvorexant - a novel dual orexin receptor antagonist. J Neurogenet 2011;25:52-61
   PubMed Web of Science ®Google Scholar
• Alvarez CE, Sutcliffe JG. Hypocretin is an early member of the incretin gene family. Neurosci Lett 2002;324:169-72
   PubMedGoogle Scholar
• Sakurai T, Nagata R, Yamanaka A, et al. Input of orexin/hypocretin by a genetically encoded neurons revealed tracer in mice. Neuron 2005;46:297-308
   PubMed Web of Science ®Google Scholar
• Shibahara M, Sakurai T, Nambu T, et al. Structure, tissue distribution, and pharmacological characterization of xenopus orexins. Peptides 1999;20:1169-76
   PubMedGoogle Scholar
• Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74
   PubMed Web of Science ®Google Scholar
• Date Y, Ueta Y, Yamashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA 1999;96:748-53
   PubMed Web of Science ®Google Scholar
• Elias CF, Saper CB, Maratos-Flier E, et al. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 1998;402:442-59
   PubMed Web of Science ®Google Scholar
• Nambu T, Sakurai T, Mizukami K, et al. Distribution of orexin neurons in the adult rat brain. Brain Res 1999;827:243-60
   PubMed Web of Science ®Google Scholar
• Lu XY, Bagnol D, Burke S, et al. Differential distribution and regulation of ox1 and ox2 orexin/hypocretin receptor messenger RNA in the brain upon fasting. Horm Behav 2000;37:335-44
   PubMed Web of Science ®Google Scholar
• Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001;435:6-25
   PubMed Web of Science ®Google Scholar
• Trivedi P, Yu H, MacNeil DJ, et al. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 1998;438:71-5
   PubMed Web of Science ®Google Scholar
• Tsujino N, Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci 2013;7:28
   PubMedGoogle Scholar
• Mieda M, Hasegawa E, Kisanuki YY, et al. Differential roles of orexin receptor-1 and-2 in the regulation of non-REM and REM sleep. J Neurosci 2011;31:6518-26
   PubMed Web of Science ®Google Scholar
• Boutrel B, Cannella N, de Lecea L. The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Res 2010;1314:103-11
   PubMed Web of Science ®Google Scholar
• Boutrel B, Kenny PJ, Specio SE, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA 2005;102:19168-73
   PubMed Web of Science ®Google Scholar
• Boutrel B, Steiner N, Halfon O. The hypocretins and the reward function: what have we learned so far? Front Behav Neurosci 2013;7:59
   PubMedGoogle Scholar
• Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66
   PubMed Web of Science ®Google Scholar
• Chen Q, de Lecea L, Hu Z, et al. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2014; doi: 10.1002/med.21326
   Google Scholar
• Gotter AL, Roecker AJ, Hargreaves R, et al. Orexin receptors as therapeutic drug targets. In: Shekhar A, editor. Orexin/hypocretin system. Elsevier Science Bv; 2012. 163-88
   Google Scholar
• Carter ME, Adamantidis A, Ohtsu H, et al. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J Neurosci 2009;29:10939-49
   PubMedGoogle Scholar
• Carter ME, Borg JS, de Lecea L. The brain hypocretins and their receptors: mediators of allostatic arousal. Curr Opin Pharm 2009;9:39-45
   PubMedGoogle Scholar
• Carter ME, Brill J, Bonnavion P, et al. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc Natl Acad Sci USA 2012;109:E2635-E44
   PubMed Web of Science ®Google Scholar
• Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76
   PubMed Web of Science ®Google Scholar
• Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000;4:57-99
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-8
   PubMed Web of Science ®Google Scholar
• Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7
   PubMed Web of Science ®Google Scholar
• Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001;30:345-54
   PubMed Web of Science ®Google Scholar
• Mignot E, Chen W, Black J. On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. Sleep 2003;26:646-9
   PubMedGoogle Scholar
• Mochizuki T, Crocker A, McCormack S, et al. Behavioral state instability in orexin knock-out mice. J Neurosci 2004;24:6291-300
   PubMed Web of Science ®Google Scholar
• Scammell TE, Willie JT, Guilleminault C, et al. A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 2009;32:111-16
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinston CM, et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003;38:715-30
   PubMed Web of Science ®Google Scholar
• Beuckmann CT, Sinton CM, Williams SC, et al. Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. J Neurosci 2004;24:4469-77
   PubMed Web of Science ®Google Scholar
• Adamantidis AR, Zhang F, Aravanis AM, et al. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007;450:420-U9
   PubMed Web of Science ®Google Scholar
• Tsunematsu T, Kilduff TS, Boyden ES, et al. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J Neurosci 2011;31:10529-39
   PubMed Web of Science ®Google Scholar
• Sasaki K, Suzuki M, Mieda M, et al. Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. PLoS One 2011;6
   Google Scholar
• Saper CB, Cano G, Scammell TE. Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol 2005;493:92-8
   PubMed Web of Science ®Google Scholar
• Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001;24:726-31
   PubMed Web of Science ®Google Scholar
• Hishikawa Y, Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Adv Neurol 1995;67:245-71
   PubMedGoogle Scholar
• Tafti M. Reply to ’promotion of sleep by targeting the orexin system in rats, dogs and humans’. Nat Med 2007;13:525-6
   PubMedGoogle Scholar
• Clark EL, Baumann CR, Cano G, et al. Feeding-elicited cataplexy in orexin knockout mice. Neuroscience 2009;161:970-7
   PubMedGoogle Scholar
• Morawska M, Buchi M, Fendt M. Narcoleptic episodes in orexin-deficient mice are increased by both attractive and aversive odors. Behav Brain Res 2011;222:397-400
   PubMedGoogle Scholar
• Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 2004;101:4649-54
   PubMed Web of Science ®Google Scholar
• Liu M, Thankachan S, Kaur S, et al. Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci 2008;28:1382-93
   PubMed Web of Science ®Google Scholar
• Baier PC, Hallschmid M, Seeck-Hirschner M, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med 2011;12:941-6
   PubMed Web of Science ®Google Scholar
• Weinhold SL, Seeck-Hirschner M, Nowak A, et al. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res 2014;262:8-13
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Lewis I, Albert R, et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003;2:999-1017
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, et al. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001;24:429-58
   PubMed Web of Science ®Google Scholar
• Mignot E, Taheri S, Nishino S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat Neurosci 2002;5.1071-5
   PubMedGoogle Scholar
• Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007;8:171-81
   PubMed Web of Science ®Google Scholar
• Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem 2009;52:891-903
   PubMed Web of Science ®Google Scholar
• Boss C, Brisbare-Roch C, Jenck F, et al. Orexin receptor antagonism: a new principle in neuroscience. Chimia (Aarau) 2008;62:974-9
   Web of Science ®Google Scholar
• Mignot E. The perfect hypnotic? Science 2013;340:36-8
   PubMedGoogle Scholar
• Jenck F, Brisbare-Roch C, Scherz M, et al. Reply to ’promotion of sleep by targeting the orexin system in rats, dogs and humans’ - Brisbare-Roch et al. Reply. Nat Med 2007;13:526-6
   Web of Science ®Google Scholar
• Black SW, Morairty SR, Fisher SP, et al. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013;36:325-36
   PubMed Web of Science ®Google Scholar
• Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;330:142-51
   PubMed Web of Science ®Google Scholar
• Betschart C, Hintermann S, Behnke D, et al. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J Med Chem 2013;56:7590-607
   PubMedGoogle Scholar
• Mang GM, Durst T, Burki H, et al. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 2012;35:1625-35
   PubMedGoogle Scholar
• Hoyer D, Durst T, Fendt M, et al. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci 2013;7:235
   PubMedGoogle Scholar
• Langtry HD, Benfield P. Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40:291-313
   PubMed Web of Science ®Google Scholar
• Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs. A review. Psychopharmacology (Berl) 1996;126:1-16
   PubMed Web of Science ®Google Scholar
• Bettica P, Squassante L, Groeger JA, et al. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012;37:1224-33
   PubMed Web of Science ®Google Scholar
• Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand? Neuropeptides 2013;47:477-88
   PubMed Web of Science ®Google Scholar
• APA. Diagnostic and statistical manual of mental disorders 5th edition. American Psychiatric Association; Arlington, VA: 2013
   Google Scholar
• Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006). Available from: https://clinicaltrials.gov/ct2/results?term=NCT00792298&Search=Search
   Google Scholar
• Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 2012;26:1088-95
   PubMedGoogle Scholar
• Bettica P, Nucci G, Pyke C, et al. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol (Oxf) 2012;26:1058-70
   PubMedGoogle Scholar
• Bettica P, Squassante L, Zamuner S, et al. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 2012;35:1097-104
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Jennum P, Plazzi G. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Med 2013;14:775-81
   PubMed Web of Science ®Google Scholar
• Merck. Newsroom. FDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia 2013. Available from: www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-belsomra-suvorexant-treatment-insomnia [Last accessed 14 Sept 2014]
   Google Scholar
• Callander GE, Olorunda M, Monna D, et al. Kinetic properties of "dual" orexin receptor antagonists at Ox1R and Ox2R orexin receptors. Front Neurosci 2013;7:230
   PubMedGoogle Scholar
• Morairty SR, Revel FG, Malherbe P, et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One 2012;7:15
   Google Scholar
• FDA. Highlights of prescribing information: belsorma® (suvorexant) tablets. 2014. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/204569s000lbledt.pdf [Last accessed 14 September 2014]
   Google Scholar
• Fleming JA. REM sleep abnormalities and psychiatry. J Psychiatry Neurosci 1994;19:335-44
   PubMedGoogle Scholar
• Hasler G, Drevets WC, Manji HK, et al. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004;29:1765-81
   PubMed Web of Science ®Google Scholar
• Germain A, Nielsen TA. Sleep pathophysiology in posttraumatic stress disorder and idiopathic nightmare sufferers. Biol Psychiatry 2003;54:1092-8
   PubMed Web of Science ®Google Scholar
• Weinhold SL, Seeck-Hirschner M, Nowak A, et al. Wake-REM sleep transitions for measuring REM sleep disturbance: comparison between narcolepsy, idiopathic hypersomnia and healthy controls. Sleep Biol Rhythms 2011;9:172-7
   Google Scholar
• Uslaner JM, Tye SJ, Eddins DM, et al. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 2013;5:179ra44
   PubMed Web of Science ®Google Scholar